The Journal of Allergy and Clinical Immunology
Volume 121, Issue 3 , Pages 671-677, March 2008

Aeroallergen sensitization correlates with PC20 and exhaled nitric oxide in subjects with mild-to-moderate asthma

  • Timothy J. Craig, DO

      Affiliations

    • Divisions of Pulmonary, Allergy, and Critical Care, Pennsylvania State University College of Medicine, Hershey, Pa
    • Corresponding Author InformationReprint requests: Timothy J. Craig, DO, Thoracic Medicine Professional Services, Pennsylvania State University College of Medicine, H041, Hershey, PA 17033-0853.
  • ,
  • Tonya S. King, PhD

      Affiliations

    • Division of Public Health Sciences, Department of Medicine, Pennsylvania State University College of Medicine, Hershey, Pa
  • ,
  • Robert F. Lemanske Jr., MD

      Affiliations

    • Division of Allergy, Immunology, Department of Pediatrics, University of Wisconsin, Madison, Wis
  • ,
  • Michael E. Wechsler, MD

      Affiliations

    • Pulmonary Division, Department of Medicine, Brigham and Women's Hospital, Boston, Mass
  • ,
  • Nikolina Icitovic, MS

      Affiliations

    • Division of Public Health Sciences, Department of Medicine, Pennsylvania State University College of Medicine, Hershey, Pa
  • ,
  • Ronald R. Zimmerman Jr., BA

      Affiliations

    • Division of Public Health Sciences, Department of Medicine, Pennsylvania State University College of Medicine, Hershey, Pa
  • ,
  • Stephen Wasserman, MD

      Affiliations

    • Division of Allergy, Immunology, Department of Medicine, University of California, San Diego, Calif
  • ,
  • National Heart, Lung, and Blood Institute's Asthma Clinical Research Network

Received 14 August 2007; received in revised form 14 November 2007; accepted 12 December 2007. published online 31 January 2008.

Background

Aeroallergen sensitization in adult asthmatic patients from a wide geographic area has not been correlated with patients' characteristics, markers of airways inflammation, and lung function.

Objective

We assessed data obtained from the Asthma Clinical Research Network trials to determine the relationship of aeroallergen sensitization to age, sex, ethnicity, and markers of inflammation and airways function.

Methods

Skin testing (14 epicutaneous) was performed on 1338 subjects with objectively diagnosed mild-to-moderate asthma from 11 Asthma Clinical Research Network studies. Skin testing used identical techniques and a quality assurance program to ensure uniformity across centers.

Results

Ninety-five percent of the subjects had at least 1 positive skin test response. Of these, 14% had positive reactions to 1 or 2 allergens and 81% had positive reactions to 3 or more allergens, and 2% of subjects reacted only to seasonal allergens, 26% only to perennial allergens, and 67% to both. Increasing IgE and exhaled nitric oxide values, decreasing PC20 values, and minority ethnicity significantly correlated with the number of positive skin test responses. Subjects with late-onset asthma were less likely to be sensitized; nonetheless, 89% of subjects older than 60 years had positive responses.

Conclusion

Ninety-five percent of patients with mild-to-moderate asthma might have an allergic component. Age does not significantly affect aeroallergen sensitization, but the pattern of allergic sensitization varies with ethnicity and geography. Measures used to characterize asthma, such as IgE, exhaled nitric oxide, and PC20 values, are correlated with aeroallergen sensitization.

Key words: Asthma, allergy, skin testing, aeroallergens, exhaled nitric oxide, IgE, methacholine challenge

Abbreviations used: ACRN, Asthma Clinical Research Network, eNO, Exhaled nitric oxide, FVC, Forced vital capacity

 

 Supported by grants U10-HL51831, U10-HL51845, U10-HL51823, U10-HL51843, U10-HL56443, U10-HL51834, U10-HL51810, U10-HL74227, U10-HL74231, U10-HL74204, U10-HL74212, U10-HL74073, U10-HL74206, U10-HL74208, U10-HL74225, and U10-HL74218.

 Disclosure of potential conflict of interest: T. J. Craig is on the advisory board for Aventis; has consulting arrangements with Genentech/Novarits, Glaxo, Schering-Plough, and AstraZeneca; and has received research support from Schering-Plough, Merck, Glaxo, ACAAI, Methaparm, Dyax, Lev, PDL, Centacore, Sanofi-Aventis, and Altana. R. F. Lemanske has consulting arrangements with Novartis, Merck, GlaxoSmithKline, Aventis, and AstraZeneca; has received research support from the National Heart, Lung, and Blood Institute; and is on the speakers' bureau for Merck and GlaxoSmithKline. M. E. Weshsler has consulting arrangements with Genentech, Novartis, Merck, Aerocrine, Graceway, and Schering-Plough; has received research support from GlaxoSmithKline; an is on the speakers' bureau for Genentech, Novartis, Merck, and GlaxoSmithKline. S. Wasserman has consulting arrangements with AstraZeneca, Genentech, Novartis, Tanex, Icos, Vistakon, Tanabe, and Amylin; has received research support from GlaxoSmithKline, and Schering-Plough; is on the speakers' bureau for AstraZeneca; has served as an expert witness in medical malpractice cases about anaphylaxis, asthma, and drug allergies; and has served as an expert witness on the health effects of mold exposure. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(07)03580-4

doi:10.1016/j.jaci.2007.12.1153

The Journal of Allergy and Clinical Immunology
Volume 121, Issue 3 , Pages 671-677, March 2008